Three pillars of post-pandemic launch excellence
pharmaphorum
APRIL 16, 2021
It is undeniable that 2020 was a particularly challenging year to launch non-COVID innovative prescription medicines. These are innovative prescription medicine molecules (small molecules and biologics) that are entering a given country market for the first time. We measured the pandemic impact on the launch of NAS at four levels.
72 
Let's personalize your content